Verity Pharmaceuticals presents news that is not only specific to our corporation but also lists important information that is relevant to the disease categories we do business in.


Press Releases

FDA-approved antibiotic with life-saving potential launches in Puerto Rico – March 14, 2022

Verity Pharmaceuticals and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico – February 16, 2022

Verity Pharmaceuticals and Acerus Pharmaceuticals form commercial agreement for the promotion of Natesto® in Puerto Rico – January 10, 2022

Critical bladder cancer drug now fully available after years of shortages. Health Canada releases VERITY-BCG™ bladder cancer treatment for distribution – September 9, 2021

Bladder cancer drug shortage resolved with Health Canada approval. VERITY-BCG™ bladder cancer treatment available for Canadian patients in the Spring – February 24, 2021

Debiopharm partners with Verity Pharmaceuticals for the exclusive U.S. commercialization of Trelstar® for prostate cancer – June 9, 2020

ZEULIDE DEPOT™ is now covered by the Ontario Drug Benefit (ODB) program for patients living with prostate cancer – May 29, 2020